 |
|
Cancer cells in blood can identify risk of recurrence in breast cancer
September 25, 2007Barcelona, Spain: Cancer cells circulating in the blood, or circulating tumour cells (CTCs), are known to be associated with a bad prognosis in women with metastatic breast cancer. Now, for the first time, a group of scientists have shown that they can also detect CTCs before and after chemotherapy treatment and hence may be able to identify those patients likely to have a recurrence of their cancer after such treatment in future.
Dr. Julia Jückstock, from the University of Munich, Munich, Germany, told a press conference at the European Cancer Conference (ECCO 14) today (Monday September 24) that the results could help improve the design of trials of chemotherapy in breast cancer, as well as reducing costs to health services.
The team, led by Dr. Brigitte Rack, also from Munich, set out to look at the role of CTCs in blood at the first diagnosis of breast cancer and during adjuvant chemotherapy and endocrine treatment. They analysed blood samples from 1,767 node-positive and high-risk node-negative breast cancer patients before the start of their treatment, and compared the results to those obtained from 852 of the same patients after completion of chemotherapy.
"We found that 10 percemt of patients whose blood was sampled before the start of treatment had more than one CTC, and 5 percent of these patients had more than two CTCs in approximately 20 ml of blood," said Dr. Jückstock. The presence of CTCs did not correlate with other prognostic factors such as tumour size, grading, hormonal or Her-2 status, but the scientists did see a significant correlation with the presence of lymph node metastases.
Of 24 healthy individuals used as controls, none showed more than one CTC, said the scientists. Among the 852 patients whose blood was analysed post-treatment, 11 percent were CTC positive before the start of treatment, while 7 percent had more than one CTC after completion of chemotherapy.
Of those patients who were initially CTC positive, 10 percent remained so and 90 percent had a negative CTC test after chemotherapy. Of those initially CTC negative, 93 percent remained negative, whereas 7 percent had a positive CTC result.
The advantage of screening for CTCs is that, unlike other predictive factors, including genetic signatures, it can be carried out after the completion of primary therapy, and, if needed, on other occasions during the duration of disease. Other predictive methods can only be used on diagnosis, and only once, say the scientists.
Previous work on the detection of CTCs in bone marrow had also been shown to have predictive value, said Dr. Jückstock. "It is easier to work with bone marrow, because the volume of CTCs is much higher than in blood in the case of a positive status. However, because bone marrow is not easily accessible it is difficult to use this technique on a large scale. It is very much simpler, and more patient-friendly, to take blood samples for analysis.
"We think that the persistence of CTCs after chemotherapy treatment is likely to be predictive of the likelihood of recurrence of cancer in these patients," said Dr. Jückstock, "and we will be working to analyse the prognostic value of our findings. If this proves to be the case, it will open the door to a simple way of monitoring the likely outcome of chemotherapy, as well as enabling us to target treatments more precisely. For example, for those patients who have an increased risk of recurrence, we could prolong or alter the chemotherapy regime to give them a better chance of recovery. For those who are likely to respond well to treatment, we could reduce the length of treatment and use less aggressive therapies, thus sparing unpleasant side effects.
"We expect to have these results in the next five years," she said, "and if they are as expected, we are optimistic that our research can bring about a real improvement in the way chemotherapy is used in breast cancer patients."
Federation of European Cancer Societies
"We found that 10 percemt of patients whose blood was sampled before the start of treatment had more than one CTC, and 5 percent of these patients had more than two CTCs in approximately 20 ml of blood," said Dr. Jückstock. The presence of CTCs did not correlate with other prognostic factors such as tumour size, grading, hormonal or Her-2 status, but the scientists did see a significant correlation with the presence of lymph node metastases.
Of 24 healthy individuals used as controls, none showed more than one CTC, said the scientists. Among the 852 patients whose blood was analysed post-treatment, 11 percent were CTC positive before the start of treatment, while 7 percent had more than one CTC after completion of chemotherapy.
Of those patients who were initially CTC positive, 10 percent remained so and 90 percent had a negative CTC test after chemotherapy. Of those initially CTC negative, 93 percent remained negative, whereas 7 percent had a positive CTC result.
The advantage of screening for CTCs is that, unlike other predictive factors, including genetic signatures, it can be carried out after the completion of primary therapy, and, if needed, on other occasions during the duration of disease. Other predictive methods can only be used on diagnosis, and only once, say the scientists.
Previous work on the detection of CTCs in bone marrow had also been shown to have predictive value, said Dr. Jückstock. "It is easier to work with bone marrow, because the volume of CTCs is much higher than in blood in the case of a positive status. However, because bone marrow is not easily accessible it is difficult to use this technique on a large scale. It is very much simpler, and more patient-friendly, to take blood samples for analysis.
"We think that the persistence of CTCs after chemotherapy treatment is likely to be predictive of the likelihood of recurrence of cancer in these patients," said Dr. Jückstock, "and we will be working to analyse the prognostic value of our findings. If this proves to be the case, it will open the door to a simple way of monitoring the likely outcome of chemotherapy, as well as enabling us to target treatments more precisely. For example, for those patients who have an increased risk of recurrence, we could prolong or alter the chemotherapy regime to give them a better chance of recovery. For those who are likely to respond well to treatment, we could reduce the length of treatment and use less aggressive therapies, thus sparing unpleasant side effects.
"We expect to have these results in the next five years," she said, "and if they are as expected, we are optimistic that our research can bring about a real improvement in the way chemotherapy is used in breast cancer patients."
Federation of European Cancer Societies
Breast Cancer Current Events and Breast Cancer News RSSGenetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN).
Study looks at psychological impact of gene test for breast cancer
Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind.
Second lumpectomy for breast cancer reduces survival rates
A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue.
MRI spots DCIS in mice
A new magnetic resonance imaging procedure can detect very early breast cancer in mice, including ductal carcinoma in situ (DCIS), a precursor to invasive cancer. Some of the tumors detected were less than 300 microns in diameter, the smallest cancers ever detected by MRI.
Birth size is a marker of susceptibility to breast cancer later in life
Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, according to a new study published in PLoS Medicine by researchers at the London School of Hygiene and Tropical Medicine.
Social class dictates cancer risk
Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy.
Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation
Early-stage breast cancer patients who exhibit limited lymph node involvement may not require post-surgery radiation therapy (RT) when they receive neoadjuvant chemotherapy before a mastectomy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
New predictive tool can help determine treatment of breast cancer patients
A new predictive measurement, called a PEPI score, could bring good news to many women diagnosed with early stage breast cancer - a low PEPI (preoperative endocrine prognostic index) score could show that they have little risk of relapse and can safely avoid chemotherapy after surgery.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
More Breast Cancer Current Events and Breast Cancer News Articles
 | The Breast Cancer Survivor's Fitness Plan (Harvard Medical School Guides) by Carolyn M. Kaelin, Francesca Coltrera, Josie Gardiner, Joy Prouty The only breast cancer recovery program designed by a Harvard doctor and survivor and approved by the American Council on Exercise (ACE) Feel healthy again. Regain control of your life. Exciting new research reveals that regular exercise can reduce the chance of breast cancer recurrence and extend your life. Exercise can also help you recover energy, strength, and flexibility diminished by... |
 | Breast Cancer Husband : How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond by Marc Silver A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time. When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give... |
 | Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second... |
 | Choices in Breast Cancer Treatment: Medical Specialists and Cancer Survivors Tell You What You Need to Know (A Johns Hopkins Press Health Book) A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions.Within these pages is a team of private consultants -- including surgeons, medical... |
 | Chicken Soup for the Breast Cancer Survivor's Soul: Stories to Inspire, Support and Heal (Chicken Soup for the Soul) by Jack Canfield, Mark Victor Hansen, Mary Olsen Kelly Your support group in a book, filled with boundless strength and profound hope - until the fight is won. Along with the shock, fear and loss many women face upon a breast cancer diagnosis comes unexpected strength, wisdom, and strong networks of sharing, support and healing. In Chicken Soup for the Breast Cancer Survivor's Soul, survivors and their family members talk openly about how difficult... |
 | Breast Cancer: Real Questions, Real Answers by David Chan Breast Cancer: Real Questions, Real Answers is an outgrowth of Dr. David Chan's more than 20 years in private oncology practice. Inspired by his patients—who courageously face their illness but often feel fearful, confused about their options, and full of questions—Dr. Chan's book is uniquely structured as a Question and Answer between patient and doctor. It provides readers with an easily... |
 | I Am Not My Breast Cancer: Women Talk Openly About Love and Sex, Hair Loss and Weight Gain, Mothers and Daughters, and Being a Woman with Breast Cancer by Ruth Peltason I Am Not My Breast Cancer gathers the warm, loving, frank, and informed voices of more than eight hundred women—from every state in the nation and from continents as far away as Australia and Africa—who reveal their fears, trade advice, share experiences, and express their deepest, most intimate concerns. Essential reading for any woman with this diagnosis, it offers the companionship of... |
 | Breast Cancer: The Complete Guide: Fifth Edition by Yashar Hirshaut, Peter Pressman Written by two renowned authorities who specialize in the treatment of breast cancer, a surgeon and an oncologist, this lucid step-by-step guide has established itself as the indispensable book women need to make informed decisions about the care that is right for them. Breast cancer will strike one out of every eight women in the United States. Because there have been many important changes in... |
 | Just Get Me Through This!: The Practical Guide to Breast Cancer by Deborah A. Cohen, M.D., Robert M. Gelfand |
 | What Your Doctor May Not Tell You About(TM): Breast Cancer: How Hormone Balance Can Help Save Your Life (What Your Doctor May Not Tell You About...) by John R. Lee, David Zava, Virginia Hopkins An informative and absorbing read for both medical practitioners and their patients, What Your Doctor May Not Tell You About Breast Cancer takes aim at "the breast cancer industry" with a barrage of thought-provoking ammunition. The book is equal parts criticism and suggestion. Current health treatments, including HRT, receive serious condemnation, and authors John Lee and David Zava carefully... |
| © 2008 BrightSurf.com |